PCSK9 and familial hyperaldosteronism: PCSK9 inhibitors have expanded therapeutic options: evolocumab is approved for patients ≥ 10 years with heterozygous FH, showing a 38% LDL-C reduction at 12 weeks in the HAUSER-RCT trial without major safety concerns [62], and alirocumab has recently been approved from age 8 years as an adjunct to statins with reassuring safety data [63].